Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Cost-effectiveness of pregabalin: a UK perspective

Johnston, Ann and Hamandi, Khalid 2007. Cost-effectiveness of pregabalin: a UK perspective. Expert Review of Pharmacoeconomics & Outcomes Research 7 (4) , pp. 327-333. 10.1586/14737167.7.4.327

Full text not available from this repository.


The management of epilepsy and neuropathic pain poses a substantial burden on individuals and society with significant healthcare resource implications. Pregabalin has been approved for add-on treatment of adults with partial seizures with or without secondary generalization and for central and peripheral neuropathic pain syndromes. New antiepileptic drugs, such as pregabalin, have higher acquisition costs than established ‘off-patent’ drugs, but boast advantages in terms of efficacy, tolerability and side-effect profiles. There is, however, scant health economic research concerning the use of any current antiepileptic drugs used to treat epilepsy and neuropathic pain. This article reviews the available data on pregabalin. There are currently insufficient data to draw conclusions on cost–effectiveness regarding its use in epilepsy, neuropathic pain or other nonepileptic conditions. Long-term retention studies and prescribing practices may give an indication as to the effectiveness and tolerability of pregabalin and consequent cost–effectiveness analyses may then prove useful.

Item Type: Article
Date Type: Publication
Status: Published
Schools: MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Subjects: R Medicine > R Medicine (General)
Publisher: Expert Reviews Ltd
ISSN: 1473-7167
Last Modified: 04 Jun 2017 08:41

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item